UK’s NICE rejects use of Gilead’s Yescarta on NHS over cost concerns
The National Institute for Health and Care Excellence (NICE) has recommended against the use of Gilead’s Yescarta (axicabtagene ciloleucel) on…
Gilead
-
-
Sierra Oncology acquires Gilead’s momelotinib in $198m deal
Canada-based drug development company Sierra Oncology has acquired Gilead Sciences’ momelotinib, a drug candidate being developed to treat myelofibrosis, in…
-
Kite partners with Gadeta to develop new cancer therapies
Gilead subsidiary Kite has formed a strategic alliance with Dutch drug discovery company Gadeta for the development of new gamma…
-
Gilead’s Yescarta secures positive opinion from Europe’s CHMP
Gilead Sciences subsidiary Kite has secured a positive recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for…
